Pfizer has acquired 50% stake in IGNITE Immunotherapy, an oncolytic virus vaccine design, discovery, and development company.

Pfizer will have two seats on IGNITE’s board of directors and collaborate on the latter’s research programme for discovery of potential novel vaccinia viruses, as part of the transaction.

Furthermore, Pfizer will fund the research and development for three years and have an option to acquire IGNITE upon completion of the initial research programme.

"Pfizer aims to strengthen its position in next-generation immuno-oncology field through the acquisition."

Pfizer aims to strengthen its position in next-generation immuno-oncology field through the acquisition.

Both companies involved are based in the US.

South Korean financial services provider KDB Capital has acquired 6.7% stake in Anygen by purchasing 333,334 shares in the latter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The target company is also based in South Korea and engaged in peptide synthesis.